BAC
Bank of America Corporation
BAC has a slight edge over FHI overall, supported by stronger fundamentals and stronger valuation.
FHI
Federated Hermes, Inc.
FHI has slightly lower modeled downside risk, despite its lower overall score.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
FHI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
FHI's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like FHI.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over FHI in the historical PE scenario, which offers more potential upside but is not a forecast.
FHI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.5x | $52.45 | -17% |
| Fair | 11x | $62.14 | -2.2% |
| Current | 11x | $63.52 | — |
| Forward | 11x | $63.52 | — |
| Expensive | 13x | $71.76 | +13% |
Historical ranges are pointers, not guarantees.
FHI's PE is in its fair range at 11.5x. If earnings grow as analysts expect, today's price would be 10.8x next year's earnings.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
FHI Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for FHI, with profitability improving.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
FHI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.89 | +6.6% |
| Q3 2026 | $5.53 | +14% |
| Q2 2026 | $5.37 | +18% |
| Q1 2026 | $5.15 | +43% |
| Q4 2025 | $5.13 | +59% |
| Q3 2025 | $4.83 | +56% |
| Q2 2025 | $4.55 | +57% |
| Q1 2025 | $3.59 | +2.3% |
| Q4 2024 | $3.23 | -5% |
FHI earned $5.53 per share over the past year, up 14% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
FHI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $507.3M | +8.1% |
| Q2 2026 | $502.8M | +18% |
| Q1 2026 | $479M | +13% |
| Q4 2025 | $482.8M | +14% |
| Q3 2025 | $469.4M | +15% |
| Q2 2025 | $424.8M | +5.5% |
| Q1 2025 | $423.5M | +6.9% |
| Q4 2024 | $424.7M | +8.5% |
FHI has the edge over BAC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | +2.6 points |
| Q2 2026 | 26% | -1.1 points |
| Q1 2026 | 26% | -4.7 points |
| Q4 2025 | 28% | +2.1 points |
| Q3 2025 | 28% | +0.2 points |
| Q2 2025 | 28% | +17 points |
| Q1 2025 | 31% | +6.2 points |
| Q4 2024 | 26% | -0.2 points |
FHI has the edge over BAC on profitability, with a higher operating margin.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
FHI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $120.2M | +18% |
| Q2 2026 | $79.7M | +343% |
| Q1 2026 | $24M | +80% |
| Q4 2025 | $161.6M | +28% |
| Q3 2025 | $101.6M | -15% |
| Q2 2025 | $18M | -78% |
| Q1 2025 | $13.3M | -1% |
| Q4 2024 | $126.2M | -1% |
FHI's free cash flow was $386M over the past year, up 49% from the year before. Free cash flow isn't a meaningful measure for financial services companies like FHI.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over FHI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
FHI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -950K shares |
| 1 year | -4.1% | -3.1M shares |
| 3 years | -15% | -12.7M shares |
| 5 years | -24% | -22.3M shares |
| Available history | -27% | -26.3M shares |
FHI has 71M diluted shares, down 4.1% from a year ago, with $263M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $57.4M |
| Q2 2026 | $64M |
| Q1 2026 | $64.7M |
| Q4 2025 | $77.1M |
| Q3 2025 | $21,000 |
| Q2 2025 | $65.5M |
| Q1 2025 | $120.1M |
| Q4 2024 | $23.4M |
FHI spent $263M buying back its own shares over the past year, up 26% from the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
FHI Net Leverage
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
FHI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.8 | Neutral |
| Stochastic | 60.5 | Neutral |
FHI's weekly RSI is 62 (neutral) and its Stochastic is 60 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
FHI PE vs Financial Services Sector
| Metric | FHI | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 13x | 12% below |
| PE % | 55 | 63 | 8 pts below |
FHI has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
FHI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $58.6 | 8.3% above |
| 20 week MA | $59.8 | 6.2% above |
| 50 week MA | $57.0 | 11% above |
| 100 week MA | $50.8 | 25% above |
| 200 week MA | $43.4 | 46% above |
FHI has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
FHI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.7 | $28.5 | -13% |
| 2021 | $28.5 | $37.4 | +31% |
| 2022 | $37.4 | $35.7 | -4.4% |
| 2023 | $35.7 | $33.9 | -5.2% |
| 2024 | $33.9 | $41.4 | +22% |
| 2025 | $41.4 | $54.1 | +31% |
| 2026 YTD | $54.1 | $63.5 | +17% |
FHI has the edge over BAC on returns for 2026, with the stronger performance.